While mild gastrointestinal symptoms are common and expected during GLP-1 therapy, certain situations require prompt medical evaluation
When used together, they address multiple aspects of blood sugar regulation, resulting in more comprehensive control
has provided consultation to Acadia Pharmaceuticals, Acumen Pharmaceuticals, ALZpath, Annovis, Aprinoia Therapeutics, Artery Therapeutics, Biogen, Biohaven, BioXcel, Bristol Myers Squibb, Eisai, Fosun, GAP Foundation, Green Valley, Janssen, Karuna, Kinoxis Therapeutics, Lighthouse Pharmaceuticals, Lilly, Lundbeck, LSP/EQT Life Sciences, Mangrove Therapeutics, Merck, MoCA Cognition, New Amsterdam, Novo Nordisk, OptoCeutics, Otsuka, Oxford Brain Diagnostics, Praxis, Prothena, reMYND, Roche, Scottish Brain Sciences, Signant Health, Simcere, Sinaptica, T-Neuro, TrueBinding and Vaxxinity pharmaceutical, assessment and investment companies
International Journal of Peptide and Protein Research 40 (3-4): 333-343